Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

The article presents a study of the potential of early binding antibody (BAb) titers or different interferon-beta (IFN-b) biomarkers to predict neutralizing antibodies (NAb). The study included patients with multiple sclerosis (MS) or clinically isolated syndrome (CIS) that receive de novo IFN-b treatment. Results showed that BAb titers reliably predict Nabs, with CXCL-10 as a potential sensitive biomarker for IFN-b response and abrogation by anti-IFN-b antibodies.